Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+ HER2-Negative Metastatic Breast Cancer. Вопр. онкол. 2026, 72 (3), OF-2675. https://doi.org/10.37469/0507-3758-2026-72-3-OF-2675.